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Abstract
Background: The generation of the amyloid-β peptide (Aβ) through the proteolytic processing of the
amyloid precursor protein (APP) is a central event in the pathogenesis of Alzheimer's disease (AD). Recent
studies highlight APP endocytosis and localization to lipid rafts as important events favoring amyloidogenic
processing. However, the precise mechanisms underlying these events are poorly understood. ApoER2 is
a member of the low density lipoprotein receptor (LDL-R) family exhibiting slow endocytosis rate and a
significant association with lipid rafts. Despite the important neurophysiological roles described for
ApoER2, little is known regarding how ApoER2 regulates APP trafficking and processing.
Results: Here, we demonstrate that ApoER2 physically interacts and co-localizes with APP. Remarkably,
we found that ApoER2 increases cell surface APP levels and APP association with lipid rafts. The increase
of cell surface APP requires the presence of ApoER2 cytoplasmic domain and is a result of decreased APP
internalization rate. Unexpectedly, ApoER2 expression correlated with a significant increase in Aβ
production and reduced levels of APP-CTFs. The increased Aβ production was dependent on the integrity
of the NPxY endocytosis motif of ApoER2. We also found that expression of ApoER2 increased APP
association with lipid rafts and increased γ-secretase activity, both of which might contribute to increased
Aβ production.
Conclusion: These findings show that ApoER2 negatively affects APP internalization. However, ApoER2
expression stimulates Aβ production by shifting the proportion of APP from the non-rafts to the raft
membrane domains, thereby promoting β-secretase and γ-secretase mediated amyloidogenic processing
and also by incrementing the activity of γ-secretase.
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Background
One of the pathological hallmarks of Alzheimer's disease
(AD) is the presence of extracellular deposits of the amy-
loid beta (Aβ) protein [1]. The Aβ peptide, usually ranging
from 40 to 43 amino acids in length, derives from the pro-
teolytic processing of the amyloid precursor protein (APP)
and has a central role in AD pathology. Aβ peptide has
well-established neurotoxic effects when aggregated into
oligomeric and fibrillar states, usually seeded by the amy-
loid prone Aβ42 species [2,3] and is also able to interfere
with synaptic function, a condition that probably com-
mits neurons to cell death [4-6].
Several cell biology studies on APP metabolism have
determined that this membrane protein undergoes two
well-compartmentalized processing routes, the amy-
loidogenic and the non-amyloidogenic [7]. In the amy-
loidogenic pathway, association of APP to detergent
resistant membrane microdomains enriched in choles-
terol and glycosphingolipids, also termed lipid rafts,
would facilitate the sequential proteolysis of APP by the
BACE enzyme (β-secretase) and the γ-secretase complex,
generating CTF-β and Aβ plus the signaling related AICD
(APP intracellular domain) [8-11]. This is in contrast to
APP processing mediated by α-secretase, an enzyme
mostly localized at the cell surface and excluded from
lipid rafts, whose activity precludes Aβ formation by cut-
ting APP in the middle of the Aβ sequence [12,13]. Several
lines of evidence suggest that part of the amyloidogenic
processing of APP occurs in the endocytic pathway. There-
fore, it has been proposed that internalization of APP
increases the production of Aβ [14,15]. The tyrosine based
endocytosis motif present in the cytoplasmic domain of
APP resembles those found in the endocytic receptors low
density lipoprotein receptor (LDL-R) and transferrin
receptor (TfR), and mediates the rapid internalization of
APP through a clathrin mediated-process in coated pits
[16,17]. Mutation of the tetrapeptide YENP within the
APP endocytosis motif GYENPTY clearly decreases Aβ
generation from cell surface APP [18,19]. However, a strict
requirement of endocytosis for amyloid formation is still
a matter of debate, since endocytosis blockage by expres-
sion of a mutant form of dynamin or by directly co-patch-
ing BACE and APP at the cell surface still allowed Aβ
production [20,21]. Therefore, it is likely that different
pools of the secretase complexes regulating Aβ production
are present both at the plasma membrane and within the
endocytic pathway.
The LDL-R family of lipoprotein receptors is currently
composed of 10 members with a diverse array of ligands
with different functions, ranging from cellular cholesterol
uptake in the liver to cell specification and neuronal posi-
tioning during embryogenesis [22]. Several lines of evi-
dence support a role for these receptors in the
pathogenesis of AD, including the participation of one of
its ligands, the ε4 isoform of apolipoprotein E as major
risk factor for AD [23,24]. LDL-R related proteins (LRPs)
share many modular and common structural motifs and
usually possess at least one NPxY motif in their relatively
short cytoplasmic tail. This motif is critically required for
receptor interaction with adaptors proteins and for inter-
nalization, with the exception of LRP1, where the endocy-
tosis motif is a YATL [25]. It has been recently
demonstrated that several LRPs family members modu-
late APP processing by affecting different aspects of APP
trafficking. For example, LRP1 increases APP endocytosis
and Aβ production [26-28], while LRP1B retains APP at
the cell surface, preventing it from undergoing amy-
loidogenic processing [29]. On the other hand, the intra-
cellular trafficking protein SorLA protects cells from
generating Aβ by reducing APP trafficking to the cell sur-
face, thereby preventing it from entering the endocytic/
amyloidogenic route [30]. Additionally, a particular alter-
natively spliced isoform of rodent ApoER2 has been dem-
onstrated to interact with APP and decrease Aβ generation
upon binding the APP and ApoER2 ligands F-spondin and
reelin, respectively [31,32]. Therefore, regulated subcellu-
lar localization of APP by LDL-R family members modu-
lates Aβ production by altering APP distribution and
interaction with specific secretases (eg. α-secretases or β-
secretases).
Recent experimental and clinical evidence suggest that
increased plasma cholesterol levels are an important risk
factor for AD [33,34] Cholesterol lowering drugs decrease
Aβ levels and plaque formation in vivo and clinical studies
suggest that cholesterol lowering drugs decrease the risk of
AD [35-38]. However, data showing the opposite role for
cholesterol had also been published (for a review see
[39]), illustrating that this is a still a controversial issue.
Cholesterol reducing drugs increase sAPPα secretion with
a concomitant decrease in Aβ formation, which might
occur by shifting APP localization from lipid rafts to α-
secretase-containing regions [13,21] and/or decreasing
the activity of the amyloidogenic enzymes. In fact, choles-
terol depletion disrupts β- and γ-secretase association to
lipid rafts and causes a decrease in Aβ production [8-10]
indicating that lipid rafts are relevant sites for amyloidog-
enic processing of APP.
ApoER2 is a member of the LDL-R family that is highly
expressed in the brain [40]. This receptor has a slower
endocytosis rate compared to LRP1 [25], although its
internalization is clathrin-dependent [41]. A significant
fraction of ApoER2 is also found in lipid rafts, but the dis-
ruption of these membrane microdomains does not affect
its endocytic activity [41]. Based on its slow endocytic rate,
it was initially proposed that the physiological functions
of ApoER2 might be in signal transduction pathwaysMolecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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rather than the endocytosis of lipoproteins and other lig-
ands [25]. It is currently known that ApoER2 participates
in the reelin signaling pathway during neuronal develop-
ment [42-44], and recent evidence indicates that it also
participates in novel neuronal functions such as matura-
tion of NMDA receptor composition in the hippocampus
[45] and the regulation of long term potentiation [46,47].
Importantly, it has been determined that the ApoER2 lig-
and reelin is found in neuritic plaques of transgenic mice
overexpressing APP [48-50], suggesting a possible associ-
ation with AD. It has been shown that one splice variant
of the mouse ApoER2 receptor regulates the processing of
APP [31,51]. However, there are no studies addressing
whether full length human ApoER2 modulates APP traf-
ficking and consequently its processing. Here, we demon-
strate that ApoER2 interacts with APP and increases APP
cell surface levels while decreasing APP internalization.
However, the increased cell surface APP correlated with
increased Aβ production. In addition, ApoER2 expression
induced an increase in APP association with lipid rafts and
a decrease APP-CTFs levels, which in part could be
explained by the increase in γ-secretase activity found in
ApoER2 expressing cells. Overall our results indicate that
ApoER2 might constitute a novel modulator of APP
processing by affecting its endocytic trafficking and the
proportion of APP present in lipid rafts, as well as the
activity of the γ-secretase complex.
Results
ApoER2 cytoplasmic domain is important for increasing 
APP at the cell surface
The internalization of cell surface APP represents one of
the major pathways for generation and subsequent release
of Aβ into the extracellular space. In order to evaluate a
potential role for ApoER2 in APP metabolism, we ana-
lyzed the effect of human ApoER2 expression on APP sub-
cellular distribution in CHO cells lacking endogenous
LRP1, which is known to regulate APP processing and Aβ
levels [26-28,52]. We determined cell surface APP levels
by flow immunocytometry in cells expressing a series of
ApoER2 variants (Fig. 1A). Initially, we detected increased
cell surface APP levels in CHO-ApoER2 compared to
CHO-pcDNA3 cells. This increase is not due to an increase
in total APP, as determined in parallel experiments with
cells permeabilized with saponin (Fig 1B). apoER2 gene
produces several splice isoforms, including an isoform
lacking a 59-amino acid insert coding for a proline-rich
domain within the cytoplasmic region [53]. We then
asked whether this domain is important for the effect of
ApoER2 on APP cell surface levels. In fact, the expression
of the receptor isoform devoid of the proline-rich insert,
ApoER2ΔPro, produced an even higher increase in cell
surface APP than the observed with full length ApoER2
expression (Fig 1B and 1C). These results demonstrate
that both ApoER2 splice variants affect steady state, cell
ApoER2 increases cell surface APP levels but not total APP Figure 1
ApoER2 increases cell surface APP levels but not 
total APP. Cell surface APP (A) and total cellular APP (B) 
were assessed by FACS analysis. LRP1-null CHO cells stably 
transfected with pcDNA3 vector, ApoER2, ApoER2ΔPro, 
ApoER2ΔPro-NPXA, or ApoER2-Tless were treated with or 
without saponin and then labeled with anti-APP antibody. Pri-
mary antibody was detected with PE-conjugated goat anti-
mouse IgG. Values are the average of triplicate determina-
tions. Error bars indicate S.E. C, lysates were prepared from 
CHO-pcDNA3 and ApoER2-expressing cells and equal 
amounts of protein were subjected to 10% SDS-PAGE. Blots 
were probed with anti-HA and anti-β-tubulin antibodies.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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surface APP levels and suggest that the proline-rich
domain partially inhibits the mechanism(s) responsible
for the increment of cell surface APP.
In order to determine whether the molecular determi-
nants for the ApoER2-induced effect on APP trafficking
are located in the cytoplasmic domain of the receptor, we
analyzed APP cell surface levels in CHO cells expressing
the internalization mutants of ApoER2 [41]. We have pre-
viously determined that truncation of the entire intracel-
lular domain of ApoER2 (tail less version of ApoER2)
promotes its accumulation within intracellular compart-
ments in CHO cells (mostly endoplasmic reticulum)
thereby preventing its access to the cell surface. However,
a single point mutation (Y/A) in the NPxY sequence of the
ApoER2ΔPro isoform abolishes its endocytosis, thereby
increasing cell surface ApoER2ΔPro levels. Importantly,
both mutated receptors still retain its ability to bind RAP,
indicating that alterations imparted to the receptors do
not affect their folding and ligand binding [41]. Therefore,
we analyzed APP cell-surface levels in CHO-ApoER2-Tai-
less and CHO-ApoER2ΔPro-NPxA cells. Deletion of the
ApoER2 C-terminal domain completely abolished the
ApoER2-induced effect on APP subcellular localization. In
contrast, the mutation of the NPxY motif within
ApoER2ΔPro construct caused an additional slight
increase in APP cell surface levels, suggesting that reduced
endocytosis of ApoER2 promotes APP accumulation at
the cell surface (Fig. 1A, B). These results demonstrate that
ApoER2 regulates APP subcellular location and that the
cytoplasmic domain of the receptor is important to
accomplish this increase in cell surface levels of APP.
ApoER2 interacts with APP695 independently of its 
cytoplasmic domain
Given the functional interaction between APP and
ApoER2, we then performed co-immunoprecipitation
experiments in N2a cells in order to test whether these
proteins do interact. We choose N2a cells because this cell
type lacks detectable expression for any of the LDL-R fam-
ily members [41]. We lysed N2a cells expressing both
APP695-Myc and ApoER2-HA and immunoprecipitated
APP with anti-Myc antibody. Western blot of immunopre-
cipitates probed with anti-HA indicates that ApoER2 co-
precipitates with APP (Fig. 2A, Upper panel). Blots were
stripped and re-blotted with anti-Myc to demonstrate that
APP695 was effectively immunoprecipitated (Fig. 2A,
Lower panel). Neither anti-Myc nor anti-HA immunoreac-
tive bands were seen in lysates immunoprecipitated with
the non-related immunoglobulin anti-V5 antibody,
which efficiently immunoprecipitates β-catenin-V5 (Fig.
2A and Fig. 2B, Lower panel), demonstrating that true
immune complexes were isolated. As a control for specif-
icity of the anti-Myc antibody, similar experiments were
performed in ApoER2-expressing cells not transfected
with APP695-Myc. The anti-Myc antibody does not
immunoprecipitate ApoER2-HA (Fig. 2B, Upper panel) but
do immunoprecipitates APP695-Myc (Fig. 2B, middle
panel) in single transfected cells, demonstrating that
ApoER2 precipitation with anti-Myc requires the APP pro-
tein. For testing an in vivo requirement for this interaction,
independent lysates from ApoER2-HA and APP695-Myc
expressing cells were incubated together and then immu-
noprecipitated with anti-Myc. No ApoER2-HA was
detected in the APP695-Myc-containing immunoprecipi-
tate (Fig. 2C). These results strongly suggest that APP and
ApoER2 directly interact in N2a cells.
To determine whether this interaction occurs through the
intracellular domain of both proteins, we analyzed co-
immunoprecipitation of APP695-Myc with ApoER2 in
N2a cells transiently transfected with APP695-Myc and
stably expressing HA-tagged wild type ApoER2- or
ApoER2-Tailess, which in the case of N2a cells is able at
least in part to get the plasma membrane [41]. When the
immunoprecipitates were blotted with anti-HA, we found
that both wild type ApoER2 and ApoER2-Tless co-immu-
noprecipitated with APP695 (Fig. 3), indicating that the
intracellular domain of the receptor is dispensable for the
interaction with APP.
ApoER2 co-localize with APP695 at the plasma membrane 
and within early endocytic vesicles
The finding that ApoER2 interacts with APP and modu-
lates APP cell surface levels led us to determine whether
both proteins co-localize in cortical and hippocampal
neurons, where both proteins are naturally expressed.
Both in transfected cortical neurons expressing APP695-
Myc and ApoER2-HA, as well as in hippocampal neurons
where endogenous proteins were immunodetected, APP
colocalizes with ApoER2 at the cell surface (Fig. 4A, C). In
addition, we observed co-localization in a perinuclear
region resembling recycling compartments and/or the
trans-Golgi network (Fig. 4B). As ApoER2 and APP are
internalized through a clathrin-mediated process, we
asked whether both proteins could actually be co-inter-
nalized from the cell surface. APP and ApoER2 co-inter-
nalization was assessed using an immuno-labeling assay
in living cells. N2a cells expressing APP695-Myc and
ApoER2-HA were incubated at 4°C with anti-Myc and
anti-HA antibodies. After washing, the cells were then
warmed to 37°C for different periods of time to initiate
endocytosis, followed by fixation, permeabilization and
staining with Alexa-conjugated secondary antibodies. In
cells that were labeled and processed at 4°C, we found
that both proteins co-localized, analyzing the samples by
both conventional (Fig. 5A, 0 min) and confocal (Fig. 5B)
microscopy. The XZ-plane analysis shows a co-localiza-
tion at the cell surface in co-transfected cells. As early as 2
minutes after warming, most of the ApoER2 immunoflu-Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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orescence was still confined to the cell surface but a small
fraction of ApoER2 was observed within intracellular
punctuate structures that also contain APP immunoreac-
tivity (Fig. 5A, 2 min, arrowheads). The intracellular co-
localization of both proteins was more evident with
longer incubation times. The XZ-plane analysis at 10 min
demonstrates co-localization within endocytic vesicles.
Only background was observed when using antibodies
against intracellular proteins or secondary antibodies only
in control experiments (data not shown). These results
provide direct evidence that APP and ApoER2 localize to
the same subcellular compartments upon endocytosis
and suggest that increased APP cell surface levels might be
the result of a direct interaction of ApoER2 and APP at the
cell surface.
ApoER2 diminishes APP695 endocytosis and increases Aβ 
production
The ApoER2-induced increase in steady state cell surface
APP levels could be caused either by a decrease in APP
internalization or by increased recycling of APP to the cell
surface. In order to analyze this point, we analyzed APP
endocytosis in CHO LRP1-null cells transiently trans-
fected with APP695HA along with increasing amounts of
ApoER2 interacts with APP in N2a cells Figure 2
ApoER2 interacts with APP in N2a cells. (A), co-immunoprecipitation of ApoER2 with APP. Cell extracts were prepared 
from ApoER2-expressing cells transiently transfected with APP695-Myc. Extracts were immunoprecipitated with anti-Myc or 
with the unrelated, anti-V5 antibody and probed for ApoER2 and APP with the anti-HA and anti-Myc antibodies, respectively. 
L, input lysate. NB, not bound. (B), cell extracts were prepared from untransfected ApoER2-expressing cells and processed as 
in A. anti-Myc antibody does not immunoprecipitate ApoER2 by itself. Middle panel, anti-Myc antibody do immunoprecipitate 
APP695Myc in single transfected cells. Lower panel, anti-V5 antibody immunoprecipitation idoneity was confirmed by β-catenin-
V5 precipitation from transfected N2a cells. (C), independent lysates from ApoER2-expressing cells and from APP695-Myc-
transfected cells were combined and the co-immunoprecipitation experiment was continued with the anti-Myc antibody as in 
A. ApoER2-HA and APP695-Myc requires an in vivo context for interaction. Remnants of ApoER2 detection after stripping and 
reblot are indicated by an asterisk.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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ApoER2. Cell surface APP was bound to 125I-antiHA at
4°C. After 1 h the cells were washed and warmed for dif-
ferent times, and cell surface and internalized pools of
APP were determined as the radioactivity in acid labile-
and cell associated-fractions, respectively [25]. Results
were plotted as % inside-to-total at each time point. The
endocytosis rates are defined considering the ligand inter-
nalization half-times, corresponding to the time required
for a 50% internalization to occur [25,54]. APP695 was
rapidly internalized with an estimated half-time of 2 min-
utes (Fig. 6A, Additional File 1: Table I). Interestingly, the
expression of ApoER2 caused a dose-dependent increase
in the half-time of APP695 internalization and a decrease
in the extent of APP695 internalization (Additional File 1:
Table I). To confirm that this effect was due to ApoER2
expression, cells from parallel experiments were lysed and
proteins were analyzed for steady state ApoER2 and APP
expression by Western blot (Fig. 6C). Increased ApoER2
expression was detected where decreased APP endocytosis
is observed, suggesting that the effect directly depends on
ApoER2 expression. As both ApoER2 and APP can be
endocytosed by a clathrin mediated processes [17-19,41]
we reasoned that the effect of ApoER2 might be due to a
simple competition for limited, ubiquitous endocytic fac-
tors. To rule out this possibility, the same experiments
were performed, but iodinated diferric transferrin instead
of anti-HA was now used as a ligand for endocytosis
kinetic determinations. The transferrin receptor possesses
a very fast initial endocytic rate (half-time of Tfr internali-
zation < 2 min) [55] (Fig. 6B). Expression of even the
highest levels of ApoER2 (Fig. 6C) did not alter the inter-
nalization kinetics of the transferrin receptor, demonstrat-
ing that the expression of ApoER2 specifically alters the
efficiency of APP endocytosis (Additional file 1: Table I).
These results strongly suggest that the increased cell sur-
face APP levels observed in ApoER2-expressing cells are
due to a specific effect in APP endocytosis.
A growing body of evidence has established members of
the LDL-R family as key regulators of the amyloidogenic
processing of APP. During the course of this study, find-
ings published by the work of Hoe et al [32] also demon-
strated that ApoER2 interacts with APP and that this
interaction can be regulated by the extracellular APP lig-
ApoER2 and APP colocalization in hippocampal neurons Figure 4
ApoER2 and APP colocalization in hippocampal neu-
rons. Primary cortical neurons were co-transfected with 
APP-Myc and ApoER2-HA and the receptors immunode-
tected in non-permeabilized (A) and permeabilized (B) cells 
using anti-Myc and anti-HA antibodies (C) Hippocampal pri-
mary neurons were permeabilized and labeled for total APP 
and ApoER2 with anti-APP(6E10) and C-terminal anti-
ApoER2, respectively. APP695-Myc and ApoER2-HA partially 
co-localize at the soma surface (A, arrows) and within neuro-
nal processes (arrowheads). A strong co-localization of APP 
and ApoER2 in a perinuclear region of permeabilized cells for 
both overexpressed (B) and endogenous levels (C) was evi-
denced.
ApoER2 and APP interact independently of the cytosolic  domain of ApoER2 Figure 3
ApoER2 and APP interact independently of the 
cytosolic domain of ApoER2. Cell extracts were pre-
pared from ApoER2- and ApoER2 Tailess-expressing N2a 
cells transiently transfected with APP695-Myc. Extracts were 
immunoprecipitated with anti-Myc and probed for ApoER2 
and for APP with the anti-HA and anti-Myc antibodies, 
respectively. Remnants of ApoER2 detection after stripping 
and reblot are indicated by an asterisk.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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and F-spondin, causing a net decrease in Aβ production
but increased APP and ApoER2-CTF levels. However, the
ApoER2 isoform used in that work corresponds to a
mouse variant lacking 3 ligand binding repeats in the
extracellular domain. Therefore, we asked whether human
full length ApoER2, as well as several ApoER2 variants
that alter APP subcellular distribution (Fig. 1), might also
modify Aβ secretion in CHO cells lacking LRP1. Condi-
tioned media from cells expressing different ApoER2 iso-
forms and mutants were collected and analyzed for Aβ40
and Aβ42 by ELISA. Unexpectedly, Aβ40 levels were signifi-
cantly increased in cells expressing both ApoER2 and
ApoER2ΔPro isoforms (Fig. 7A). The increase in Aβ40 lev-
els was dependent on the integrity of the NPxY motif,
indicating that the ApoER2 endocytosis and/or the
recruitment of cytosolic proteins were required for this
processing to occur. To gain further insight into a positive
correlation between increased cell surface APP and
increased Aβ production, we analyzed Aβ levels in CHO
cells expressing the ApoER2-Tailess mutant, which does
not reach cell surface [41]. Cells expressing this construct
do not show an increase in cell surface APP (Fig. 1). Con-
sistently, the truncation of the cytoplasmic domain of
ApoER2 abolishes the ApoER2-induced increase in Aβ40
levels (Fig. 7A). To test whether the more pathologically
relevant Aβ42 was also modulated by ApoER2, we simi-
larly determined Aβ42  levels by ELISA in conditioned
media from ApoER2-expressing cells. Aβ42 levels paral-
leled those of Aβ40 in most of the cell lines analyzed. How-
ever, Aβ42 was increased only in cells expressing the full
length receptor but not in cells expressing ApoER2ΔPro
isoforms (Fig. 7B). Collectively, these results demonstrate
that ApoER2 modulates trafficking and processing of APP
towards the amyloidogenic pathway at the cell surface and
in an isoform dependent way, a new scenario for regu-
lated APP processing induced by an LDL-R family mem-
ber.
ApoER2 increases APP695 association to lipid rafts but 
decreases APP-CTF
Recent retrospective clinical studies [35,36] as well as sev-
eral in vitro and in vivo evidence [37,38,56] support the
hypothesis that increased cellular cholesterol levels
increase APP metabolism through the amyloidogenic
pathway and that decreasing cholesterol levels increases
non-amyloidogenic processing [13]. Cellular cholesterol
effects on the amyloidogenic processing might occur by
facilitating association of APP with either the BACE or the
γ-secretase complex, which reside in detergent insoluble
membrane microdomains enriched in cholesterol, called
lipid rafts [8-11]. ApoER2 is a receptor that associates to
lipid rafts, and this characteristic is not related to its inter-
nalization pathway [41]. Therefore it is possible that the
increase in Aβ levels we determined could be explained by
an ApoER2-induced shift of APP to lipid rafts, where APP
proteolytic processing occurs. To test this possibility, we
prepared Lubrol-insoluble membrane domains from APP
or APP-ApoER2 expressing CHO LRP1-null cells at 4°C
and detected APP in lipid rafts isolated by sucrose density
gradient. As previously described for Lubrol lysed cells
[8,10], most of the cellular APP was present in the non-
rafts fractions (9 to 11); however ApoER2 expression led
to a 1.2 fold increase (measured densitometrically) in the
proportion of APP associated to lipid rafts (not shown).
Interestingly when γ-secretase activity was inhibited with
DAPT [57] we found that APP was better detected in lipid
rafts fractions. The lipid raft pool of APP was further incre-
mented when ApoER2 was co-expressed (Fig. 8A). Densi-
tometric analysis of Western blots indicates that ApoER2
expression causes a 2.2 fold increase in APP distribution
into lipid rafts (Fig. 8B). Detection of the receptor in the
same membranes, with an anti-ApoER2 antibody, con-
firms the receptor expression only in transfected cells and
demonstrates that fully-glycosylated, mature ApoER2 and
full length APP coexist at the same buoyancy membrane
fractions. The gradients sucrose profile and caveolin-1 dis-
tribution for control and ApoER2 co-transfected cells were
similar, confirming that protein overexpression does not
alter the integrity of lipid rafts (Fig. 8A). Considering that
ApoER2 and APP co-localize at the cell surface and within  internalization vesicles of N2a cells Figure 5
ApoER2 and APP co-localize at the cell surface and 
within internalization vesicles of N2a cells. N2a cells 
were transiently transfected with ApoER2-HA and APP695-
Myc and surface-immunolabeled with anti-HA and anti-Myc 
antibodies for 60 min at 4°C. The cells were then shifted to 
37°C for varying periods of time, to allow internalization to 
occur. (A) Prior to warming (t0), ApoER2 and APP immun-
ofluorescence was confirmed at the cell membrane (arrows). 
Partial co-immunolocalization (arrowheads) was detected as 
early as 2 min after endocytosis in punctuate structures near 
the cell membrane. By 10 minutes, most of the immunoreac-
tivity was confined to deeper internalized vesicles, as visual-
ized by confocal XZ-plane analysis (B) at t0 and t 10 min.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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ApoER2 and APP can be co-immunoprecipitated (Fig. 2)
and that both proteins co-localize, at the plasma mem-
brane and after co-internalization (Fig. 4, Fig. 5) these
results strongly suggest that the effect of ApoER2-induced
APP raft localization might be direct.
To further support the notion of an ApoER2-induced amy-
loidogenic processing of APP, we asked whether ApoER2
expression modifies APP-CTF levels. It has been previ-
ously determined that in addition to the amyloidogenic
secretase machinery and a small proportion of APP, lipid
rafts also contain APP-CTFs and Aβ [10,58]. Therefore we
analyzed the effect of ApoER2 expression in the levels of
APP-CTF fragments obtained in the lipid rafts from
Lubrol-extracted cells. Under control conditions, APP-
CTFs were not detected in cells expressing APP695 (Addi-
tional file 2, A left panels). In fact, it has been shown that
the detection of APP-CTF fragments critically depends on
the inhibition of γ-secretase activity [10,59]. Then, in the
presence of DAPT, we were able to detect clearly APP-CTFs
(Additional file 2, A right panels). In both cases we
detected ApoER2-CTFs but also ApoER2-ICDs, which sug-
ApoER2 expression specifically decreases APP695HA endocytosis Figure 6
ApoER2 expression specifically decreases APP695HA endocytosis. Dose-response effect of ApoER2 expression on 
APP695HA (A) and diferric transferrin (B) endocytosis. CHO-LRP null cells transiently transfected with APP695HA alone (solid 
square) or along with 5 μg (solid inverted triangle), 10 μg (open triangle) or 20 μg (open inverted triangle) of an ApoER2 cod-
ing plasmid were incubated with 1 nM 125I-labeled-anti-HA IgG or 5 nM 125I-labeled-diFeTf for 1 h at 4°C and then shifted to 
37°C for the indicated times. The percent of ligand internalized at each time point is equal to the amount of ligand internalized 
divided by the total cell-associated ligand (see "Materials and Methods") Values are the mean average of triplicate determina-
tions with S.E. indicated by error bars. (C) Lysates were prepared from similarly transfected cells and equal amounts of protein 
were subjected to 10% SDS-PAGE. Blots were probed with anti-HA, anti-ApoER2, anti-actin or anti-transferrin receptor (TfR) 
antibodies. ApoER2 expression decreases APP695 but not transferrin receptor endocytosis rate.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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gests an incomplete inhibition of γ-secretase activity in the
presence of DAPT (Additional file 2B). We then character-
ized the effect of ApoER2 expression on the processing of
endogenous and transfected APP (in the presence of
DAPT). Surprisingly, ApoER2 expression significantly
decreased the steady state levels of APP-CTFs in CHO
LRP1-null cells expressing endogenous (hamster) APP or
transfected human APP695 (Fig. 9A). Western blot analy-
ses from total cell lysates denoted similar human APP
expression in both conditions (Fig. 9B). Collectively,
these results indicate that ApoER2 increases full-length
APP association to rafts but diminishes APP-CTF levels,
suggesting that ApoER2 regulates APP processing in mul-
tiple steps.
The decreased levels of APP-CTFs and the presence of
more Aβ suggest that the basal activity of the amyloidog-
enic processing enzymes could be enhanced in cells
expressing ApoER2. However the fact that the levels of
APP-CTF are decreased in the presence of ApoER2 does
not necessarily support an increment in β-secretase activ-
ity. The increment in Aβ levels could be explained for a
more efficient γ-secretase processing on APP-CTFs in the
presence of ApoER2 and similar activity of β-secretase. To
test this hypothesis we compared γ-secretase activity from
CHAPSO-solubilized membrane fractions of N2a and
CHO LRP1-null cells expressing vector or ApoER2, by
mixing these fractions with an APP-CTF derived fluores-
cent peptide harboring the γ-secretase cleavage site. It
should be noted that CHAPSO protects the integrity of the
γ-secretase complex and hence activity and therefore has
been widely used to measure γ-secretase activity [60-63].
We found that γ-secretase activity was significantly
enhanced in two different cell lines expressing ApoER2,
N2a and CHO LRP1-null (Figure 10A). The measured
activity was sensitive to the γ-secretase inhibitor DAPT
(see methods). In N2a cells, the total amount PS1 was not
changed (Figure 10B, C), being almost exclusively in the
form of the active PS1-NTF. Interestingly in CHO cells, the
total PS1 (Holo-PS1 and PS1-NTF) related to actin was
slightly increased in cells expressing ApoER2 but the PS1-
NTF levels were clearly increased in CHO ApoER2 (Figure
10B, compare Holo-PS1 with PS1-NTF) suggesting that
the expression of the receptor could influence the autocat-
alytic activation of PS1. Our novel findings show that the
activity of γ-secretase is enhanced in cells expressing
ApoER2 and this effect could explain, at least in part, the
increment in Aβ and the decreased levels of APP-CTFs in
the same ApoER2 cells compared to the controls.
Discussion and Conclusion
In this work we assessed the role of ApoER2 in APP traf-
ficking and processing in cells that do not express LRP1,
another receptor of the LDL-R family previously described
as a modulator of APP processing [64]. Our findings show
that ApoER2 decreased APP internalization rate and
increased the amount of APP that partitions into lipid
rafts, where Aβ is produced. Interestingly, the expression
of ApoER2 also significantly increased γ-secretase activity
in two different cell types compared to controls. As a net
result of these changes, Aβ levels were significantly
Increased endogenous Aβ secretion in LRP1-null, ApoER2- expressing CHO cells Figure 7
Increased endogenous Aβ secretion in LRP1-null, 
ApoER2-expressing CHO cells. LRP1-null CHO cells sta-
bly transfected with pcDNA3 vector, ApoER2, ApoER2ΔPro, 
ApoER2ΔPro-NPXA, or ApoER2-Tless encoding plasmids 
were incubated in low serum media. After 48 h, media was 
analyzed for Aβ levels by ELISA. (A) Aβ40 and (B) Aβ42 val-
ues were normalized to the amount of cellular protein in the 
corresponding cell extracts and expressed as fold increase 
over pcDNA3-expressing cells. Values are the mean average 
of triplicate determinations with S.E. indicated by error bars.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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increased. The effects that ApoER2 has on APP trafficking
and processing might be direct, as ApoER2 and APP co-
immunoprecipitate and co-localize at the cell surface of
neuronal cells and are also found within the same intrac-
ellular vesicles upon internalization. Our results show
that ApoER2 increases Aβ production despite elevated cell
surface APP levels, due to effects on APP association with
lipid rafts and γ-secretase activity. This presents a signifi-
cant and novel mechanism for regulation of APP metabo-
lism by an LDL-R family member.
The catabolism of APP is a well-compartmentalized proc-
ess. While the predominant non-amyloidogenic pathway
occurs mostly if not exclusively at the cell surface, the less
frequent amyloidogenic branch occurs either along the
biosynthetic pathway during APP delivery to the cell sur-
face or during APP trafficking to endosomes upon inter-
nalization from the cell surface [7]. All the LDL-R family
proteins that have been demonstrated to interact with
APP and affect its processing modify APP trafficking and
change Aβ production by modulating the ratio of cell sur-
face/intracellular APP. For example, increased APP locali-
zation to intracellular compartments in cells expressing
the endocytic LRP1 receptor promotes Aβ generation
[27,28]. On the contrary, expression of the tumor sup-
pressor protein LRP1B, which has a very slow endocytic
rate, increases APP levels at the plasma membrane and
reduces Aβ production [29]. Another LRP family member,
the intracellular sorting related protein SorLA/LR11, inter-
acts with APP in intracellular compartments and modu-
lates its trafficking to the trans-Golgi network, preventing
its delivery to the cell surface for subsequent internaliza-
tion and amyloidogenic processing [30,65,66] and its
expression is decreased in AD [30]. Ectopic localization of
SorLA/LR11 or LRP1 to the cell surface increases cell sur-
face APP with a concomitant decrease in Aβ production,
highlighting that the APP amyloidogenic process is facili-
tated during the cell surface/endocytosis cycles of APP
[28,30]. In a completely opposite scenario, here we dem-
onstrated that human ApoER2 increases APP levels at the
cell surface but also increases Aβ levels from endogenous
APP in CHO LRP1-null cells. This ApoER2-mediated
effect on APP cell surface was also observed with the alter-
natively spliced ApoER2 isoform lacking the proline rich
domain. Interestingly, Aβ42 levels were increased in cells
expressing full length ApoER2 but not ApoER2ΔPro,
while Aβ40 production was increased in both. It is known
that Aβ40 is formed predominantly at the trans-golgi net-
work and endosomes, while Aβ42 is produced in earlier
intracellular compartments, mainly intermediate com-
partments and cis-Golgi cisternae [7]. Although the overall
endocytic properties of ApoER2 and ApoER2ΔPro are vir-
tually identical [41] differences in Aβ42 production might
be the result of different APP trafficking routes during the
biosynthetic pathway and/or after internalization induced
by ApoER2. Alternatively, the association of ApoER2 with
adaptor proteins that specifically interact with the proline
rich domain, such as PSD-95 or JIP-1/2, might account for
these differences [47,67,68]. Further experiments are
required to address this hypothesis.
In the course of our experiments, similar findings were
published in the work by Hoe et al. [32] showing a phys-
ical and functional interaction between ApoER2 and
APP695. In that case, however, the secreted protein F-
spondin serves as an extracellular link for the interaction
of these proteins, which results in increased cell surface
APP levels but decreased Aβ levels. Two possible explana-
tions for the discrepancies between these data and those
presented here are (i) the different ApoER2 splice variant
isoforms used and (ii) the different LRP1 status of the cell
lines utilized. In the work by Hoe et al. [32], they utilized
a mouse version of ApoER2 lacking the entire exon 5 cod-
ing for repeats 4 to 6 in the ligand binding domain, the
ApoER2 increases full length APP association to lipid rafts in  LRP1-null CHO cells Figure 8
ApoER2 increases full length APP association to lipid 
rafts in LRP1-null CHO cells. (A) Increased association of 
APP to lipid rafts in ApoER2-expressing cells. LRP1-null 
CHO cells were transiently transfected with pcDNA3 (con-
trol) and APP695-Myc (APP) or APP695-Myc along with 
ApoER2-HA, treated with 10 μM DAPT for 16 h and lipid 
rafts were isolated in Lubrol 0.5% – containing lysis buffer in 
a sucrose gradient. After concentration of sucrose gradients 
fractions, proteins were subjected to 6% SDS-PAGE, blotted 
and probed with anti-APP and anti-ApoER2 antibodies. To 
demonstrate that ApoER2 expression does not disrupts lipid 
rafts formation in APP expressing cells, 1/16 sucrose gradi-
ents fractions were subjected to 12.5% SDS-PAGE and 
probed with anti-caveolin antibody. ApoER2 increases lipid 
raft association of full length APP. (B), densitometric analysis 
of a representative Western blot experiment of (A).Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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main alternatively spliced isoform found in mouse [69].
In the present study, we used the full length ApoER2 ver-
sion containing all 15 exons encoding the extracellular
domain [70]. It is worth mentioning that ApoER2 iso-
forms lacking repeats 4 to 6 affected activated α2 M but
not β-VLDL binding to ApoER2 [71,72] suggesting that
this domain may play a role in binding APP. Although we
can not rule out that F-spondin might also increase
human full-length ApoER2 interaction with APP and
decrease Aβ secretion, this domain may be important for
ApoER2 expression decreases APP-CTFs in DAPT-treated LRP1-null CHO cells Figure 9
ApoER2 expression decreases APP-CTFs in DAPT-treated LRP1-null CHO cells. (A) ApoER2 decreases both 
endogenous hamster APP-CTFs and human APP695-CTFs. LRP1-null CHO cells were transiently transfected with pcDNA 
(control), APP695-Myc (APP) or APP695-Myc along with ApoER2-HA (APP/ApoER2). Cells were then treated with DAPT 10 μM 
and protein association to lipid rafts was analyzed as in Figure 8. High sensitivity films were used for endogenous APP-CTFs 
detection. (B), Lubrol-extracted proteins from lysates obtained in (A) were subjected to 10% SDS-PAGE. Blots were probed 
with anti-ApoER2, anti-APP and anti-actin or antibodies. Similar APP protein levels were detected in APP695-Myc and in 
APP695-Myc + ApoER2-HA transfected cells. Remnants of ApoER2 detection after stripping and reblot are indicated by an 
asterisk.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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differential binding to other ligands required for the
ApoER2-APP functional interaction to modulate Aβ pro-
duction. Importantly, two additional isoforms of human
ApoER2 lacking repeats number four to six and four to
seven in the ligand binding domain are also expressed in
the brain [70-72] but nothing is known about the regula-
tion of these isoforms during aging or in AD. On the other
hand, in our studies we also used two cell lines that lack
LRP1 which increases Aβ production but also directly
binds and internalizes Aβ [64]. The CHO LRP1-null cells
we used here were previously used for assessing the effect
of LRP1 mutants on APP processing [27,28] and in the
N2a cells, we did not inmunodetect LRPs or RAP binding
activity [41]. Therefore, and in contrast to the experimen-
tal system used before [32], in our study, we were able to
dissect these possible LRP1 mediated-events from the
effect induced by ApoER2 expression alone.
Early biochemical assays utilizing cell surface radioiodi-
nation and endocytosis inhibition by potassium deple-
tion highlighted the importance of APP endocytosis in Aβ
production [18], and subsequent evidence with APP
mutants clearly defined molecular determinants required
for clathrin-mediated endocytosis of APP and Aβ produc-
tion [19,27]. Our results show that ApoER2 decreases
endocytosis of APP but surprisingly, increases Aβ produc-
tion. Recent evidence indicates that APP can also be proc-
essed at the cell surface. Endocytosis inhibition by
expression of the dominant negative Dynamin-1 protein,
DynK44A, increased both Aβ and p3 secretion in HeLa
cells [20]. However, the same mutant decreased Aβ secre-
tion in HEK293 stably expressing APP695 [73]. It has
been reported that PS1 can be delivered along with Nicas-
trin to the plasma membrane in a functional complex,
where it might proteolyse Notch, Erb4, E-cadherin and
APP at the γ-secretase cleavage site [74]. Interestingly,
exciting results have been published by the work of Ehe-
halt et al. [21] showing that, despite APP endocytosis is
required for Aβ production, co-patching of BACE and APP
at cell surface lipid rafts bypasses the detrimental effect of
APP endocytosis inhibition on amyloidogenic processing
arguing that cell surface Aβ production can take place in
particular conditions within surface lipid rafts. In our
work, we demonstrated that ApoER2 increased the
amount of APP fractionating into lipid rafts. Therefore, an
increased amyloidogenic processing of APP at plasma
membrane lipid rafts might explain the effects induced by
ApoER2 (i.e. increased association to lipid rafts and
decreased endocytosis rate) and reconcile the increased
Aβ production and decreased APP internalization we have
observed. Consistent with this notion, LRP1 has been
recently recognized as a BACE substrate and both LRP1
and BACE interact at the cell surface [75], suggesting that
other LDL-R family members, including ApoER2, might
also be processed by BACE along with the interacting pro-
ApoER2 expression enhances γ-secretase activity Figure 10
ApoER2 expression enhances γ-secretase activity. 
N2a and CHO LRP1-null cells expressing full length ApoER2 
or transfected with pcDNA3 alone were lysed in CHAPSO 
containing buffer. (A), Measurement of γ-secretase activity 
using a fluorogenic substrate assay, which is based on the 
secretase-dependent cleavage of a γ-secretase-specific sub-
strate conjugated with a fluorescent molecule. Data repre-
sent mean ± S.E.M of three experiments in duplicated, 
presented as fold values of the basal activity. * P < 0.05, ** P 
< 0.01. (B), 50 μg of protein/lane were subjected to 12% 
SDS-PAGE and endogenous PS1 levels were determined by 
Western blot. In N2a cells almost all PS1 is detected as PS1-
NTF but in CHO LRP1-null cells a significant amount of 
Holo-PS1 is also detected. ApoER2 expression increases 
PS1-NTF and decreases Holo-PS1 compared to control 
CHO LRP1-null cells. The expression of actin was deter-
mined in the same blot as a loading control. (C), densitomet-
ric analysis of Western blots as in (B) confirms that total PS1 
levels were slightly increased in CHO-ApoER2 cells com-
pared to the pcDNA3 cells. However, a further increase in 
the PS1-NTF fraction is clearly observed in the Western 
blot.Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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tein APP. As lipid rafts are also located to intracellular
compartments (early endosomes, TGN and recycling ves-
icles [76]), we can not rule out however that APP that is
slowly endocytosed by interaction with ApoER2 expres-
sion might routed via clathrin-dependent endocytosis to a
lipid raft enriched intracellular compartment for amy-
loidogenic processing where ApoER2, BACE and the γ-
secretase complex have been detected [11,14,41,77-79].
In addition to the increase in APP present in lipid rafts,
our results also show a new and interesting effect of
ApoER2 expression on the γ-secretase activity. The novel
results support the possibility that the increased Aβ levels
might also result from increased γ-secretase activity
induced by ApoER2 within intracellular compartments.
Supporting this model, recently published evidence by Pei
and colleagues showed that, β-adrenergic receptor activa-
tion induces PS1 endocytosis through a clathrin-mediated
process and increases Aβ production [62]. Therefore, an
ApoER2-induced delivery of APP to lipid rafts and an
increase in γ-secretase activity might also provide the basis
of the increased Aβ production by ApoER2 we have
observed. Despite our results linking ApoER2 expression
with APP-CTFs do not suggest an induction in β-secretase
activity, we cannot discard that ApoER2 expression also
modifies this proteolytic activity.
Cholesterol positively regulates γ-secretase and Aβ selec-
tively regulates key enzymes for cholesterol metabolism
[80]. On the other hand, the raft associated ApoER2 is also
a  γ-secretase substrate that is proteolytically processed
upon apoE binding [31,81]. Therefore we suggest that
neuronal ApoER2 would have a physiological role in APP
processing and function, which could be functionally
connected to the neuronal lipid homeostasis. Deregula-
tion of a concerted APP/ApoER2 processing might play a
role in the pathogenesis of Alzheimer's disease.
Methods
Cell lines and cell tissue culturing
Parental CHO LRP-1 null cells were grown in F12HAM/
10%FBS supplemented with 100 U Penicillin, 1 U Strep-
tomycin and 5 μg/mL Plasmocin. The ApoER2-HA,
ApoER2-ΔPro-HA, ApoER2-ΔPro-NPXA-HA and
ApoER2Tless-HA-expressing CHO LRP1-null cells have
been previously described [41] and were grown in the
presence of 400 μg/mL G418. Parental N2a were grown in
DMEM/7.5% FBS supplemented with 100 U Penicillin, 1
U Streptomycin and 5 μg/mL Plasmocin. ApoER2-HA and
ApoER2-Tless-HA-expressing N2a cells [41] were main-
tained in growing medium supplemented with 400 μg/
mL G418. CHO and N2a cells were transfected using
Lipofectamine2000 and different amount of plasmid as
noted. For control experiments, total DNA was kept con-
stant by including empty pcDNA3 vector in the transfec-
tion mixture. Three h after the addition of the DNA-
liposome complexes, the cells were washed with PBS and
grown overnight in serum-containing media without anti-
biotics.
Determination of cell surface APP levels by FACS in CHO 
LRP-1 null clones
Cells (4 × 106) were plated and grown overnight in 100
mm Petri dishes. Cells were washed with PBS and incu-
bated at 37°C in 3 mL PBS-EDTA 1 mM for 5 min. After
the addition of 3 mL complete medium, cells were
mechanically detached and collected (40% or 60% of the
total) by centrifugation at 700 × g for 5 min in a 15 mL
conical tube. The smaller pellet was dissolved in 160 μL
PFN (1.5% heat-inactivated FBS, 0.1% NaN3 in PBS) and
kept on ice. The remaining cells were resuspended in 160
μL PFN-saponin 0.05% and gently mixed at 4°C for 30
min. Permeabilized cells were similarly collected by cen-
trifugation at 4°C for 10 min and resuspended in 160 μL
PFN. Permeabilized and non-permeabilized cells were
then equally divided to two microcentrifuge tubes, and 50
μL PFN (control samples) or 50 μL PFN containing 50 ng/
μL of anti-APP (6E10, Signet, previously used to detect
endogenous APP from CHO cells, [29]) were added. After
gently rocking the tubes at 4°C for 60 min, cells were
washed twice with 800 μL PFN or PFN-saponin 0.05%,
respectively and resuspended in 50 μL PFN or 50 μL PFN-
saponin 0.05% containing 20 μg/mL PE-conjugated don-
key anti-mouse IgG (Molecular Probes), respectively.
After 40 min secondary antibody incubation at 4°C, cells
were similarly washed and resuspended in 300 μL PFN for
FACS determinations in a FACScalibur cytometer (Beck-
ton & Dickinson). Surface and total APP fluorescence was
represented as the geometric mean of fluorescence inten-
sity from non-permeabilized and permeabilized cells,
respectively, after the subtraction of the corresponding
blank controls. Results are plotted as % of pcDNA3 con-
trol.
ApoER2 and APP co-immunoprecipitation in N2a cells
4 × 106 cells of ApoER2-HA or ApoER2-Tless-HA-express-
ing N2a cells were grown overnight in 100 mm Petri
dishes. Cells were washed twice with PBS and transfected
with 30 μg of APP695-Myc plasmid [29] using
Lipofectamine2000. 48 h after transfection, the cells were
washed twice with PBS and lysed 30 min at 4–10°C in
500 μL Buffer HUNT (20 mM Tris-HCl pH 8.0, 100 mM
NaCl, 1 mM EDTA, 1% NP40, 0.5% TX-100, 50 mM NaF)
supplemented with 2 mM PMSF and 2× protease inhibi-
tors cocktail. After debris removal by centrifugation, cell
lysates were precleared with 20 μL agarose-protein A/G
(Pierce) for 30 min at 4°C and then incubated for 2 h at
4°C with 5 μg anti-Myc (clone 9E10, Roche) with gentle
rocking. 40 μL agarose-protein A/G (Pierce) was then
added, and the mixtures were incubated for 1.5 h at 4°CMolecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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with gentle rocking. Beads were washed three times with
1 mL Buffer HUNT supplemented with 1 mM PMSF,
boiled in 30 μL reducing Laemli Buffer and 7.5% SDS-
PAGE was performed. Anti-V5 (Invitrogen) was used as a
non-related antibody and mock transfected ApoER2-HA-
expressing cells or APP695-Myc only expressing cells were
used as controls. For the in vivo requirement experiment,
parental N2a cells were analogously transfected in a 60
mm plate and equivalent HUNT lysates from APP-trans-
fected and ApoER2-HA-expressing cells were combined
and the standard protocol was followed.
Colocalization analysis in primary rat hippocampal and 
cortical neurons
Hippocampal and cortical neurons were obtained and
cultured as described [82]. Dissociated cells were plated
on glass-coverslips coated with 1 mg/ml poly-L-lysine in
medium containing 10% horse serum (Invitrogen). After
3 hr, the medium was supplemented with N2 (Invitrogen)
[83]. Cells were transiently transfected on day 7 with plas-
mids encoding APP695-myc and ApoER2-HA using Lipo-
fectAMINE 2000. After 18 h, neurons were fixed with 4%
PFA and 4% sucrose for 20 min at 37°C, and processed for
immunofluorescence as described previously [84]. For
cell surface staining, incubation with primary or second-
ary antibodies was performed before permeabilization
with detergents (saponin). Endogenous detection was
assessed in hippocampal neurons using anti-APP (6E10,
Signet) and anti C-terminal ApoER2 antibodies. Stained
cells were analyzed with an inverted microscope (Leica,
DM2000) equipped with epifluorescence filters and pho-
tographed using a 100× objective. Alternatively, a Zeiss
laser scanning confocal microscope was used to collect X-
Y sections in 0.45 μm using a 60× objective.
Co-endocytosis of ApoER2-HA and APP695-Myc in N2a 
cells
N2a cells (8 × 105) were plated in 35 mm Petri dishes and
grown overnight. Cells were washed twice with PBS and
transfected with plasmids encoding APP 695-Myc (4.5
μg), ApoER2-HA (1.75 μg) and RAP (1.75 μg). After 24 h,
the cells were tripsinized and grown in 6 × 10 mm cover-
slips for an additional day. The cells were chilled on ice for
30 min, washed twice with ice-cold PBS and incubated
with 30 μL Binding Buffer (2% BSA in DMEM) containing
1 μg/mL chicken anti-Myc (AB3252, Chemicon) and 1:30
dilution of an anti-HA hybridoma supernatant (Clone
12CA5) for 90 min at 4°C. After washing away excess anti-
body with PBS, the cells were incubated with 1 mL pre-
warmed Binding Buffer for the indicated times at 37°C.
Endocytosis was immediately stopped by quickly washing
the cells with ice-cold PBS and incubating in 600 μL PFA
2% for 20 min. The cells were permeabilizaed in PBS/
saponin 0.2% for 10 min and nonspecific binding sites
were blocked with PBS/gelatin 0.2% for 1 h. A mixture of
2  μg/mL donkey anti-mouse Alexa 488 (Molecular
Probes) and donkey anti-chicken Alexa 596 (Molecular
Probes) secondary antibodies in PBS/gelatin 0.2% was
added for 30 min at 37°C and the covers were mounted
with DABCO and analyzed either by indirect immunoflu-
orescence with Leica microscope or by confocal micros-
copy. As a control, cells transfected with 8 μg of pcDNA3
were similarly processed.
Preparation and radioiodination of Diferric transferrin and 
anti-HA
Diferric transferrin (diFeTf) was prepared from apotrans-
ferrin (apoTf) as described previously [85] with some
modifications. 87.5 μL of 10 mg/mL human apoTf in 0.1
M Hepes-KOH pH 7.4 were combined with 3.5 μL of 5
mM Fe(NTA)2. After adding 109 μL of 1 M NaHCO3, the
mixture was incubated 30 min at 37°C, and full satura-
tion of apoTf with Fe was monitored by an Abs465/280 ratio
of 0.044. Routinely, diFeTf was obtained at 90% satura-
tion. The anti-HA antibody was purified as previously
described and eluted in PBS [29]. 25–50 μg of protein was
iodinated in 10 mM sodium phosphate buffer pH 7.5 in a
total reaction volume of 100 μL with 1–2 mCi Na [125I] by
using IODOGEN(Pierce)-treated tubes. After 10 min incu-
bation at room temperature, free iodine was removed by
passing the mixture through a PD-10 desalting column
(GE healthcare) and iodinated proteins were recovered as
one mL eluted fractions. Specific activities of radioligands
usually ranged from 30,000 to 50,000 cpm/ng and were
stored at 4°C until use.
Radioligand endocytosis in transfected CHO LRP-1 null 
cells
4 × 106 cells were plated in 100 mm Petri dishes and
grown overnight. Cells were washed twice with PBS and
transfected with a mixture of plasmids containing 20 μg
APP695-HA [29], 5 μg RAP and ranging from 5 to 20 μg
ApoER2 as noted using Lipofectamine 2000. Total DNA
was kept constant by including empty pcDNA3 vector
where needed. 24 h after transfection, the cells were split
into 15 wells of a single column of five 12-well multi-
plates for the endocytosis assay, as well as 2 wells for West-
ern blot analysis. After an additional 24 hours of culture,
the cells were chilled on ice for 30 min, washed twice with
ice cold Binding Buffer (0.6% BSA in F12HAM) and incu-
bated 1 h at 4°C with 500 μL Binding Buffer containing 1
nM  125I-anti-HA. After eliminating unbound antibody
with two cold Binding Buffer washes, the cells were incu-
bated with 1 mL pre-warmed Binding Buffer and incu-
bated for indicated times at 37°C. Endocytosis was
stopped by immediately placing the plate on ice and add-
ing 1 mL cold Stop Strip solution (0.2 M acetic acid, 100
mM NaCl, pH 2.6). Cell surface radioligands were
detached from cells twice by incubating the cells in 1 mL
Stop Strip for 10 min at 4°C, and internalized radiolig-Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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ands were then recovered by lysing cells in 1 mL Low SDS
Buffer (62.5 mM Tris-HCl, 0.2% SDS, 10% glycerol, pH
6.8). Acid labile and endocytosed fractions were counted
in a γ-counter and plotted as % internalized-to-total radi-
oactivity ratio versus time. As a specificity control for the
antibody, radioactivity measurements were corrected by
subtracting the corresponding background radioactivity
obtained from similarly processed, control cells. The time
at which 50% internalization occurs was referred as the
internalization half-time and is inversely related to the
endocytosis rate. The same protocol was used for diFeTf
endocytosis, except that cells were pre-incubated for 2 h
with Binding Buffer at 32°C for maximal recovery of TfR
at the cell surface prior to binding of 125I-diFeTf, 5 nM.
Verification of protein expression levels by Western blot
Overnight cultures were scraped in lysis buffer (PBS con-
taining 1% TX-100) supplemented with 1 mM PMSF and
a protease inhibitor cocktail for 30 min at 4°C. After
nuclei and debris removal by centrifugation, proteins
were quantified and 30 μg proteins were subjected to 10%
SDS-PAGE and transferred to PVDF membranes. Lysates
from gradients were directly used for quantification and
Western blotting. In the case of PS1 determination cell
extracts were prepared in CHAPSO buffer (50 mM Tris-
HCl, 2 mM EDTA, protease inhibitors (Roche), 0.25%
CHAPSO pH 6.8). PVDF membranes were blocked with
PBS/5% low fat milk and incubated O/N with PBS/5%
low fat milk supplemented with the indicated antibody
and 0.05% Tween 20 for anti-APP (CT695, Zymed;
1:500), anti-HA (mouse hybridoma supernatant; 1:100),
anti-TfR (H68.4, Zymed; 1:1,000), anti-PS1 (1:5,000),
[86] anti-actin (MAB1501R, Chemicon; 1:4,000); or 0.1%
Tween 20 for anti-ApoER2 antiserum (1:3,000) at 4°C in
a roller. After 3 washes, the membranes were incubated 3
h at room temperature in a roller with HRP coupled anti-
mouse IgG antibody (Sigma; 1:5,000) or HRP coupled
anti-rabbit HRP (Sigma; 1:10,000). After 4 washes, the
membranes were incubated with 10 mL enhanced chemi-
luminescence reagent and low or high sensitivity films
were appropriately used. Quantification of bands was per-
formed using the MATRIX (Quantavision) software.
Aβ40 and Aβ42 determinations
CHO LRP-1 null stable clones (1 × 105 cells) were plated
in 35 mm Petri dishes and grown for 48 h. After washing
the cells twice with PBS, the cells were grown in 800 μL
F12HAM/1%FBS supplemented with antibiotics and 400
μg/mL G418 for additional 48 h. Conditioned media were
collected, centrifuged at 20,000 × g for 5 min at 4°C and
Aβ40 and Aβ42 concentrations in the cleared conditioned
media were determined by sandwich ELISA as previously
described [28]. Briefly, serial dilutions of Aβ40 and Aβ42
in F12HAM/1%FBS were prepared for standard curves.
100  μL freshly thawed conditioned media or standard
dilutions were subjected to ELISA sandwich using anti-
Aβ1–42  (21F12) or anti-Aβ13–28  (266) antibody-covered
plates. After overnight incubation at 4°C, wells were
extensively washed with guanidine containing buffer, and
biotin-conjugated anti-Aβ13–28  (266) antibody or anti-
Aβ1–40 (2G3) were added for Aβ40 and Aβ42 detection,
respectively. After 90 min incubation at 37°C, avidin-con-
jugated HRP was added for 90 min, and ELISA was devel-
oped with TMB substrate in a SoftMax ELISA machine,
reading the plate at 650 nm every 2 min. For normaliza-
tion, total protein extracts were prepared from the same
growing plates by scrapping the cells in lysis buffer (TX-
100 1% in PBS) supplemented with 1 mM PMSF and a
protease inhibitor cocktail. After nuclei and debris
removal by centrifugation, proteins were quantified and
Aβ levels were normalized to protein content per well.
Immunodetection of full-length and CTFs of ApoER2 and 
APP in lipid rafts
4 × 106 cells were grown overnight in 100 mm Petri
dishes. Cells were washed twice with PBS and transfected
with a mixture of plasmids containing either 20 μg APP, a
mixture of 5 μg RAP and 5 μg ApoER2 or both using Lipo-
fectamine 2000. Mock transfected cells were used as a neg-
ative control for endogenous APP detection. 24 h after
transfection, the cells were split into two 100 mm Petri
dishes and treated overnight with 10 μM DAPT or vehicle.
The cells were then chilled on ice for 30 min, washed
twice with cold PBS, scraped in Lysis Buffer (25 mM MES
pH 6.5, 150 mM NaCl, 0.5% Lubrol WX) supplemented
with 2 mM PMSF and a 2× protease inhibitors cocktail
and incubated on ice for 1 h with periodic vortexing.
Lysates were passed through a G27 needle 5 times and
debris was removed by centrifugation at 10,000 × g for 3
min at 4°C. 500 μL of lysate were combined with 500 μL
of 80% sucrose in MBS (25 mM MES pH 6.5, 150 mM
NaCl) and briefly mixed by vortex. Subsequently, 2 mL of
35% sucrose and 2 mL 5% sucrose in MBS were carefully
added for discontinuous gradient formation and samples
were centrifuged at 130,000 × g for 18 h at 4°C in an
AH650 Sorvall Rotor. Twelve 400 μL fractions were recov-
ered from top to bottom, and 300 μL were precipitated by
the methanol/chloroform method [87]. Total precipitated
proteins were subjected to Tris-Tricine SDS-PAGE for
ApoER2- and APP-CTF immunodetection or to 6% SDS-
PAGE for full length ApoER2/APP immunodetection by
Western blot. In some experiments, gradient fractions
were subjected to sucrose content determination and
caveolin-1 immunodetection as previously described
[41].
γ-Secretase-mediated peptide cleavage assay
γ-Secretase activity was assayed in vitro using an APP-CTF
derived intramolecularly quenched fluorescent peptide
according to the manufacturers' instructions (Calbio-Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
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chem) [60,63]. Briefly, cellular membranes from N2a and
CHO cell were prepared as described [63] and solubilized
in CHAPSO buffer (50 mM Tris-HCl, 2 mM EDTA, pro-
tease inhibitors (Roche), 0.25% CHAPSO pH 6.8) fol-
lowed by incubation at 37°C for different times in 150 μl
of assay buffer containing 50 mM Tris-HCl, protease
inhibitors (Roche), 2 mM EDTA, 0.25% CHAPSO, pH 6.8
and 8 μM fluorescent APP-CTF derived peptide (Calbio-
chem). After incubation, the reaction mixture was centri-
fuged (16,100 × g, 15 min) and the supernatant
transferred to a 96 well plate. Fluorescence was measured
using a Perkin Elmer Luminescence spectrometer LS50B
(excitation/emission at 350/440 nm). Specific γ-secretase
activity was determined after subtracting the fluorescence
obtained in the presence of DAPT (10 μM). Background
fluorescence was calculated by incubating separately 50
μg of CHAPSO-solubilized P2 membranes and 8 μM APP-
CTF derived peptide with assay buffer for different times
and mixing them just before fluorescence determination.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
RAF was a postdoctoral fellow in Dr. Marzolo's lab and
carried out most of the experiments described in this arti-
cle, contributed with the analysis of the data and worked
in the figures and manuscript preparation. MIB contrib-
uted significantly to the work performing the first obser-
vations of APP cell surface levels and Aβ production and
also making many stable cell lines used in this study. JL
and JC performed the ELISA measurements of Aβ and con-
tributed with their expertise in the result's interpretation.
CA and CAE contributed with the γ-secretase activity
measurements. NI contributed in the beginning of this
project with his expertise in Aβ and with the results inter-
pretation and support. GB and FB significantly contrib-
uted conceptually to the design of some experiments and
helped to draft the manuscript. MPM is the corresponding
author, contributing intellectually with the conception of
the project and analysis and interpretation of the data,
direction of the personnel and also participated in the
manuscript writing. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
We would like to thank Dr. Andrés Norambuena and Dr. Isabel Yuseff for 
their critical advice during the course of the experiments, to Dr. Tulio 
Nuñez (University of Chile) for providing us with technical support and 
material for the transferrin endocytosis assay and Dr. Willem Annaert 
(Katholieke Universiteit Leuven) for providing the PS1 antibody. We thank 
to Dr. Maria Rosa Bono (University of Chile), Dr. Alex Kalergis and Dr. 
Leandro Carreño (Pontificia Universidad Católica de Chile) for assistance 
with FACS experiments and Claudio Retamal (Pontificia Universidad 
Católica de Chile) for his technical help in the immunofluorescence micro-
scopy experiments. We also thank to Jane Knisely (Washington University 
in St Louis) for improving final redaction of the manuscript before submis-
sion. This work was supported by FIRCA grant TW006456 to GB and 
MPM, Fondo de Investigación Avanzada en Areas Prioritarias (FONDAP) 
Grant 13980001, the Millenium Institute for Fundamental and Applied Biol-
ogy (MIFAB) to MPM and NCI, National Institute on Aging grant R01 
AG027924 to G.B., a grant from the Alzheimer's Association to G.B., and a 
grant from the American Health Assistant Foundation to G.B. Rodrigo 
Fuentealba was a postdoctoral fellow supported by FONDAP and MIFAB.
References
1. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy.
Physiol Rev 2001, 81(2):741-766.
2. Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R,
Wood SJ, Camilleri P, Roberts GW: Aggregation state and neu-
rotoxic properties of Alzheimer beta-amyloid peptide.  Neu-
rodegeneration 1995, 4(1):23-32.
3. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L,
Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G,
Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T:
Abeta42 is essential for parenchymal and vascular amyloid
deposition in mice.  Neuron 2005, 47(2):191-199.
4. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos
M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C,
Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands
derived from Abeta1-42 are potent central nervous system
neurotoxins.  Proc Natl Acad Sci U S A 1998, 95(11):6448-6453.
5. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lam-
bert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL: Syn-
aptic targeting by Alzheimer's-related amyloid beta
oligomers.  J Neurosci 2004, 24(45):10191-10200.
6. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M,
Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE:
Early-onset behavioral and synaptic deficits in a mouse
model of Alzheimer's disease.  Proc Natl Acad Sci U S A 2006,
103(13):5161-5166.
7. Annaert W, De Strooper B: A cell biological perspective on
Alzheimer's disease.  Annu Rev Cell Dev Biol 2002, 18:25-51.
Additional file 1
Table 1 – ApoER2 expression affects the extent of APP695HA inter-
nalization and the half-time of 125I-antiHA internalization in a dose 
dependent manner. Parameters were calculated from sigmoidal fit of 
data from Figure 6.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-2-14-S1.pdf]
Additional file 2
Figure: Effect of DAPT treatment on APP and ApoER2 CTFs. LRP1-
null CHO cells were transiently transfected with plasmids encoding 
APP695-Myc or ApoER2-HA. After 24 h, cells were incubated with 10 
μM DAPT or vehicle (DMSO) for 16 h and lipid rafts were then isolated 
in a sucrose gradient. After concentration of the sucrose gradients frac-
tions, proteins were subjected to Tris Tricine-PAGE, blotted and probed 
with anti-APP (A) and anti-ApoER2 (B) antibodies. DAPT treatment 
improves APP-CTFs detection. However apparently there is still remaining 
activity that explains the presence of ApoER2-ICDs, resulting from 
processing of ApoER2-CTFs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-2-14-S2.tiff]Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
Page 17 of 19
(page number not for citation purposes)
8. Riddell DR, Christie G, Hussain I, Dingwall C: Compartmentaliza-
tion of beta-secretase (Asp2) into low-buoyant density, non-
caveolar lipid rafts.  Curr Biol 2001, 11(16):1288-1293.
9. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ: Exclu-
sively targeting beta-secretase to lipid rafts by GPI-anchor
addition up-regulates beta-site processing of the amyloid
precursor protein.  Proc Natl Acad Sci U S A 2003,
100(20):11735-11740.
10. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Siso-
dia SS, Thinakaran G: Spatial segregation of gamma-secretase
and substrates in distinct membrane domains.  J Biol Chem
2005, 280(27):25892-25900.
11. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC,
Xu H, Thinakaran G: Association of gamma-secretase with lipid
rafts in post-Golgi and endosome membranes.  J Biol Chem
2004, 279(43):44945-44954.
12. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M,
Haass C, Fahrenholz F: Constitutive and regulated alpha-secre-
tase cleavage of Alzheimer's amyloid precursor protein by a
disintegrin metalloprotease.  Proc Natl Acad Sci U S A 1999,
96(7):3922-3927.
13. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low choles-
terol stimulates the nonamyloidogenic pathway by its effect
on the alpha -secretase ADAM 10.  Proc Natl Acad Sci U S A 2001,
98(10):5815-5820.
14. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman
BT: Demonstration by FRET of BACE interaction with the
amyloid precursor protein at the cell surface and in early
endosomes.  J Cell Sci 2003, 116(Pt 16):3339-3346.
15. Kaether C, Schmitt S, Willem M, Haass C: Amyloid precursor pro-
tein and Notch intracellular domains are generated after
transport of their precursors to the cell surface.  Traffic 2006,
7(4):408-415.
16. Koo EH, Squazzo SL, Selkoe DJ, Koo CH: Trafficking of cell-sur-
face amyloid beta-protein precursor. I. Secretion, endocyto-
sis and recycling as detected by labeled monoclonal
antibody.  J Cell Sci 1996, 109 ( Pt 5):991-998.
17. Yamazaki T, Koo EH, Selkoe DJ: Trafficking of cell-surface amy-
loid beta-protein precursor. II. Endocytosis, recycling and
lysosomal targeting detected by immunolocalization.  J Cell
Sci 1996, 109 ( Pt 5):999-1008.
18. Koo EH, Squazzo SL: Evidence that production and release of
amyloid beta-protein involves the endocytic pathway.  J Biol
Chem 1994, 269(26):17386-17389.
19. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ,
Chen X, Stokin GB, Koo EH: Mutagenesis identifies new signals
for beta-amyloid precursor protein endocytosis, turnover,
and the generation of secreted fragments, including
Abeta42.  J Biol Chem 1999, 274(27):18851-18856.
20. Chyung JH, Selkoe DJ: Inhibition of receptor-mediated endocy-
tosis demonstrates generation of amyloid beta-protein at
the cell surface.  J Biol Chem 2003, 278(51):51035-51043.
21. Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic
processing of the Alzheimer beta-amyloid precursor protein
depends on lipid rafts.  J Cell Biol 2003, 160(1):113-123.
22. May P, Herz J: LDL receptor-related proteins in neurodevelop-
ment.  Traffic 2003, 4(5):291-301.
23. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM,
Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased
amyloid beta-peptide deposition in cerebral cortex as a con-
sequence of apolipoprotein E genotype in late-onset Alzhe-
imer disease.  Proc Natl Acad Sci U S A 1993, 90(20):9649-9653.
24. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Eng-
hild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity
binding to beta-amyloid and increased frequency of type 4
allele in late-onset familial Alzheimer disease.  Proc Natl Acad
Sci U S A 1993, 90(5):1977-1981.
25. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G: The YXXL
motif, but not the two NPXY motifs, serves as the dominant
endocytosis signal for low density lipoprotein receptor-
related protein.  J Biol Chem 2000, 275(22):17187-17194.
26. Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT,
Strickland DK: Modulation of beta-amyloid precursor protein
processing by the low density lipoprotein receptor-related
protein (LRP). Evidence that LRP contributes to the patho-
genesis of Alzheimer's disease.  J Biol Chem 2000,
275(10):7410-7415.
27. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH: The cyto-
plasmic domain of the LDL receptor-related protein regu-
lates multiple steps in APP processing.  Embo J 2002,
21(21):5691-5700.
28. Cam JA, Zerbinatti CV, Li Y, Bu G: Rapid endocytosis of the low
density lipoprotein receptor-related protein modulates cell
surface distribution and processing of the beta-amyloid pre-
cursor protein.  J Biol Chem 2005, 280(15):15464-15470.
29. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G: The low
density lipoprotein receptor-related protein 1B retains beta-
amyloid precursor protein at the cell surface and reduces
amyloid-beta peptide production.  J Biol Chem 2004,
279(28):29639-29646.
30. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke
J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R,
Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A,
Willnow TE: Neuronal sorting protein-related receptor
sorLA/LR11 regulates processing of the amyloid precursor
protein.  Proc Natl Acad Sci U S A 2005, 102(38):13461-13466.
31. Hoe HS, Rebeck GW: Regulation of ApoE receptor proteolysis
by ligand binding.  Brain Res Mol Brain Res 2005, 137(1-2):31-39.
32. Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck
GW: F-spondin interaction with the apolipoprotein E recep-
tor ApoEr2 affects processing of amyloid precursor protein.
Mol Cell Biol 2005, 25(21):9259-9268.
33. Wolozin B: Cholesterol and the biology of Alzheimer's dis-
ease.  Neuron 2004, 41(1):7-10.
34. Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I: Cholesterol
and Alzheimer's disease--is there a relation?  Mech Ageing Dev
2006, 127(2):138-147.
35. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and
the risk of dementia.  Lancet 2000, 356(9242):1627-1631.
36. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G:
Decreased prevalence of Alzheimer disease associated with
3-hydroxy-3-methyglutaryl coenzyme A reductase inhibi-
tors.  Arch Neurol 2000, 57(10):1439-1443.
37. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller
P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreu-
ther K, Hartmann T: Simvastatin strongly reduces levels of
Alzheimer's disease beta -amyloid peptides Abeta 42 and
Abeta 40 in vitro and in vivo.  Proc Natl Acad Sci U S A 2001,
98(10):5856-5861.
38. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Tho-
mas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE:
A cholesterol-lowering drug reduces beta-amyloid pathol-
ogy in a transgenic mouse model of Alzheimer's disease.
Neurobiol Dis 2001, 8(5):890-899.
39. Ledesma MD, Dotti CG: Amyloid excess in Alzheimer's disease:
what is cholesterol to be blamed for?  FEBS Lett 2006,
580(23):5525-5532.
40. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo
H, Saeki S, Yamamoto T: Human apolipoprotein E receptor 2. A
novel lipoprotein receptor of the low density lipoprotein
receptor family predominantly expressed in brain.  J Biol Chem
1996, 271(14):8373-8380.
41. Cuitino L, Matute R, Retamal C, Bu G, Inestrosa NC, Marzolo MP:
ApoER2 is endocytosed by a clathrin-mediated process
involving the adaptor protein Dab2 independent of its Rafts'
association.  Traffic 2005, 6(9):820-838.
42. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Cur-
ran T: Reelin is a ligand for lipoprotein receptors.  Neuron 1999,
24(2):471-479.
43. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC,
Cooper JA, Herz J: Direct binding of Reelin to VLDL receptor
and ApoE receptor 2 induces tyrosine phosphorylation of
disabled-1 and modulates tau phosphorylation.  Neuron 1999,
24(2):481-489.
44. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W,
Nimpf J, Hammer RE, Richardson JA, Herz J: Reeler/Disabled-like
disruption of neuronal migration in knockout mice lacking
the VLDL receptor and ApoE receptor 2.  Cell 1999,
97(6):689-701.
45. Sinagra M, Verrier D, Frankova D, Korwek KM, Blahos J, Weeber EJ,
Manzoni OJ, Chavis P: Reelin, very-low-density lipoproteinMolecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
Page 18 of 19
(page number not for citation purposes)
receptor, and apolipoprotein E receptor 2 control somatic
NMDA receptor composition during hippocampal matura-
tion in vitro.  J Neurosci 2005, 25(26):6127-6136.
46. Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD,
Herz J: Reelin and ApoE receptors cooperate to enhance hip-
pocampal synaptic plasticity and learning.  J Biol Chem 2002,
277(42):39944-39952.
47. Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li WP,
Adelmann G, Frotscher M, Hammer RE, Herz J: Modulation of syn-
aptic plasticity and memory by Reelin involves differential
splicing of the lipoprotein receptor Apoer2.  Neuron 2005,
47(4):567-579.
48. Wirths O, Multhaup G, Czech C, Blanchard V, Tremp G, Pradier L,
Beyreuther K, Bayer TA: Reelin in plaques of beta-amyloid pre-
cursor protein and presenilin-1 double-transgenic mice.  Neu-
rosci Lett 2001, 316(3):145-148.
49. Motoi Y, Itaya M, Mori H, Mizuno Y, Iwasaki T, Hattori H, Haga S,
Ikeda K: Apolipoprotein E receptor 2 is involved in neuritic
plaque formation in APP sw mice.  Neurosci Lett 2004,
368(2):144-147.
50. Botella-Lopez A, Burgaya F, Gavin R, Garcia-Ayllon MS, Gomez-Tor-
tosa E, Pena-Casanova J, Urena JM, Del Rio JA, Blesa R, Soriano E,
Saez-Valero J: Reelin expression and glycosylation patterns are
altered in Alzheimer's disease.  Proc Natl Acad Sci U S A 2006,
103(14):5573-5578.
51. Hoe HS, Magill LA, Guenette S, Fu Z, Vicini S, Rebeck GW: FE65
interaction with the ApoE receptor ApoEr2.  J Biol Chem 2006,
281(34):24521-24530.
52. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtz-
man DM, Bu G: Apolipoprotein E and low density lipoprotein
receptor-related protein facilitate intraneuronal Abeta42
accumulation in amyloid model mice.  J Biol Chem 2006,
281(47):36180-36186.
53. Brandes C, Novak S, Stockinger W, Herz J, Schneider WJ, Nimpf J:
Avian and murine LR8B and human apolipoprotein E recep-
tor 2: differentially spliced products from corresponding
genes.  Genomics 1997, 42(2):185-191.
54. York SJ, Arneson LS, Gregory WT, Dahms NM, Kornfeld S: The rate
of internalization of the mannose 6-phosphate/insulin-like
growth factor II receptor is enhanced by multivalent ligand
binding.  J Biol Chem 1999, 274(2):1164-1171.
55. Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN,
Dean A, Bridges KR: Receptor-mediated endocytosis of trans-
ferrin in K562 cells.  J Biol Chem 1983, 258(8):4715-4724.
56. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons
K: Cholesterol depletion inhibits the generation of beta-amy-
loid in hippocampal neurons.  Proc Natl Acad Sci U S A 1998,
95(11):6460-6464.
57. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang
LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, John-
son-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH,
Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn
KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J,
Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs
LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK,
Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Lit-
tle SP, Mabry TE, Miller FD, Audia JE: Functional gamma-secre-
tase inhibitors reduce beta-amyloid peptide levels in brain.  J
Neurochem 2001, 76(1):173-181.
58. Vetrivel KS, Thinakaran G: Amyloidogenic processing of beta-
amyloid precursor protein in intracellular  compartments.
Neurology 2006, 66(2 Suppl 1):S69-73.
59. Chen F, Yang DS, Petanceska S, Yang A, Tandon A, Yu G, Rozmahel
R, Ghiso J, Nishimura M, Zhang DM, Kawarai T, Levesque G, Mills J,
Levesque L, Song YQ, Rogaeva E, Westaway D, Mount H, Gandy S, St
George-Hyslop P, Fraser PE: Carboxyl-terminal fragments of
Alzheimer beta-amyloid precursor protein accumulate in
restricted and unpredicted intracellular compartments in
presenilin 1-deficient cells.  J Biol Chem 2000,
275(47):36794-36802.
60. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B,
Naslund J: Partial purification and characterization of gamma-
secretase from post-mortem human brain.  J Biol Chem 2003,
278(27):24277-24284.
61. Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D:
Linking receptor-mediated endocytosis and cell signaling:
evidence for regulated intramembrane proteolysis of mega-
lin in proximal tubule.  J Biol Chem 2004, 279(33):34302-34310.
62. Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z, Song M, Xiong J, Bai Y,
Pei G: Activation of beta2-adrenergic receptor stimulates
gamma-secretase activity and accelerates amyloid plaque
formation.  Nat Med 2006, 12(12):1390-1396.
63. Urra S, Escudero CA, Ramos P, Lisbona F, Allende E, Covarrubias P,
Parraguez JI, Zampieri N, Chao MV, Annaert W, Bronfman FC: TrkA
receptor activation by nerve growth factor induces shedding
of the p75 neurotrophin receptor followed by endosomal
gamma-secretase-mediated release of the p75 intracellular
domain.  J Biol Chem 2007, 282(10):7606-7615.
64. Bu G, Cam J, Zerbinatti C: LRP in amyloid-beta production and
metabolism.  Ann N Y Acad Sci 2006, 1086:35-53.
65. Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis
D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R,
Willnow TE: Molecular dissection of the interaction between
amyloid precursor protein and its neuronal trafficking recep-
tor SorLA/LR11.  Biochemistry 2006, 45(8):2618-2628.
66. Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A,
Irizarry MC, Andersen OM, Willnow TE, Hyman BT: Interaction of
the cytosolic domains of sorLA/LR11 with the amyloid pre-
cursor protein (APP) and beta-secretase beta-site APP-
cleaving enzyme.  J Neurosci 2006, 26(2):418-428.
67. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA,
Stockinger W, Nimpf J, Herz J: Interactions of the low density
lipoprotein receptor gene family with cytosolic adaptor and
scaffold proteins suggest diverse biological functions in cellu-
lar communication and signal transduction.  J Biol Chem 2000,
275(33):25616-25624.
68. Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M,
Herz J, Schneider WJ, Nimpf J: The reelin receptor ApoER2
recruits JNK-interacting proteins-1 and -2.  J Biol Chem 2000,
275(33):25625-25632.
69. Brandes C, Kahr L, Stockinger W, Hiesberger T, Schneider WJ, Nimpf
J: Alternative splicing in the ligand binding domain of mouse
ApoE receptor-2 produces receptor variants binding reelin
but not alpha 2-macroglobulin.  J Biol Chem 2001,
276(25):22160-22169.
70. Kim DH, Magoori K, Inoue TR, Mao CC, Kim HJ, Suzuki H, Fujita T,
Endo Y, Saeki S, Yamamoto TT: Exon/intron organization, chro-
mosome localization, alternative splicing, and transcription
units of the human apolipoprotein E receptor 2 gene.  J Biol
Chem 1997, 272(13):8498-8504.
71. Clatworthy AE, Stockinger W, Christie RH, Schneider WJ, Nimpf J,
Hyman BT, Rebeck GW: Expression and alternate splicing of
apolipoprotein E receptor 2 in brain.  Neuroscience 1999,
90(3):903-911.
72. Sun XM, Soutar AK: Expression in vitro of alternatively spliced
variants of the messenger RNA for human apolipoprotein E
receptor-2 identified in human tissues by ribonuclease pro-
tection assays.  Eur J Biochem 1999, 262(1):230-239.
73. Carey RM, Balcz BA, Lopez-Coviella I, Slack BE: Inhibition of
dynamin-dependent endocytosis increases shedding of the
amyloid precursor protein ectodomain and reduces genera-
tion of amyloid beta protein.  BMC Cell Biol 2005, 6:30.
74. Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, Steiner
H, Haass C: Presenilin-1 affects trafficking and processing of
betaAPP and is targeted in a complex with nicastrin to the
plasma membrane.  J Cell Biol 2002, 158(3):551-561.
75. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM,
Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ,
Sever S, Irizarry MC, Strickland DK, Hyman BT: The low density
lipoprotein receptor-related protein (LRP) is a novel beta-
secretase (BACE1) substrate.  J Biol Chem 2005,
280(18):17777-17785.
76. Rajendran L, Simons K: Lipid rafts and membrane dynamics.  J
Cell Sci 2005, 118(Pt 6):1099-1102.
77. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW: Maturation and
endosomal targeting of beta-site amyloid precursor protein-
cleaving enzyme. The Alzheimer's disease beta-secretase.  J
Biol Chem 2000, 275(43):33729-33737.
78. Rechards M, Xia W, Oorschot VM, Selkoe DJ, Klumperman J: Prese-
nilin-1 exists in both pre- and post-Golgi compartments and
recycles via COPI-coated membranes.  Traffic 2003,
4(8):553-565.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Neurodegeneration 2007, 2:14 http://www.molecularneurodegeneration.com/content/2/1/14
Page 19 of 19
(page number not for citation purposes)
79. He X, Li F, Chang WP, Tang J: GGA proteins mediate the recy-
cling pathway of memapsin 2 (BACE).  J Biol Chem 2005,
280(12):11696-11703.
80. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering
M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T: Regu-
lation of cholesterol and sphingomyelin metabolism by amy-
loid-beta and presenilin.  Nat Cell Biol 2005, 7(11):1118-1123.
81. May P, Bock HH, Nimpf J, Herz J: Differential glycosylation regu-
lates processing of lipoprotein receptors by gamma-secre-
tase.  J Biol Chem 2003, 278(39):37386-37392.
82. Banker GA, Cowan WM: Rat hippocampal neurons in dispersed
cell culture.  Brain Res 1977, 126(3):397-342.
83. Bottenstein JE, Sato GH: Growth of a rat neuroblastoma cell
line in serum-free supplemented medium.  Proc Natl Acad Sci U
S A 1979, 76(1):514-517.
84. Rosso S, Bollati F, Bisbal M, Peretti D, Sumi T, Nakamura T, Quiroga
S, Ferreira A, Caceres A: LIMK1 regulates Golgi dynamics, traf-
fic of Golgi-derived vesicles, and process extension in pri-
mary cultured neurons.  Mol Biol Cell 2004, 15(7):3433-3449.
85. Bali PK, Harris WR: Site-specific rate constants for iron
removal from diferric transferrin by nitrilotris(methyl-
enephosphonic acid) and pyrophosphate.  Arch Biochem Biophys
1990, 281(2):251-256.
86. Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P,
Craessaerts K, De Strooper B: Interaction with telencephalin
and the amyloid precursor protein predicts a ring structure
for presenilins.  Neuron 2001, 32(4):579-589.
87. Wessel D, Flugge UI: A method for the quantitative recovery of
protein in dilute solution in the presence of detergents and
lipids.  Anal Biochem 1984, 138(1):141-143.